Gastrointestinal Motility in Patients With Neuroendocrine Tumors

Status Completed

Clinical Trial Summary

We will study the total gastrointestinal transit time (GITT), gastric emptying and small intestine motility in NET patients before and after treated with somatostatin analogues and compare these to healthy subjects. For this we will use radio-opaque markers and the newly developed Motility Tracking System (MTS).

Hypothesis: Patients with NET and carcinoid syndrome have decreased GITT, gastric emptying and small bowel transit time and an increase in phase III MMC activity compared to healthy subjects. Treatment with somatostatin analogues increase transit times and decrease phase III MMC activity and improves the clinical symptoms.

Clinical Trial Description

n/a

Study Design

N/A

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00789841
Study type	Observational
Source	University of Aarhus
Contact
Status	Completed
Phase	N/A
Start date	September 2008
Completion date	May 2010

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04837885` - Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases	Phase 2
Recruiting	`NCT05069220` - 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor	Early Phase 1
Completed	`NCT05816720` - Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
Active, not recruiting	`NCT04400474` - Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study	Phase 2
Recruiting	`NCT04907643` - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes	N/A
Completed	`NCT01849523` - Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor: a Randomized Pilot Study	N/A
Recruiting	`NCT01448083` - Heart/Mediastinal Ratio Study for Potential Equivalence of Heart/Mediastinal Ratios at One and Two Hours to the Traditional Heart/Mediastinal Ratio Obtained at Four Hours	N/A
Completed	`NCT00804336` - Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors	Phase 1
Active, not recruiting	`NCT02092714` - Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors
Terminated	`NCT04073017` - Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency	N/A
Completed	`NCT00434109` - Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization	Phase 2
Completed	`NCT02472678` - Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor	N/A
Completed	`NCT02481804` - Optimal Feeding for NET Patients	N/A
Completed	`NCT02147106` - Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility Study
Completed	`NCT00165230` - Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors	Phase 2
Active, not recruiting	`NCT03012789` - Surgical Intervention and the NETest	N/A
Not yet recruiting	`NCT02038738` - 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors	Phase 1/Phase 2
Completed	`NCT01024387` - AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors	Phase 2
Terminated	`NCT00227617` - Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors	Phase 2/Phase 3
Terminated	`NCT02177773` - GA-68 DOTA-TOC of Somatostatin Positive Malignancies	Phase 1/Phase 2